When was Ansa Biotechnologies founded?

Ansa Biotechnologies was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Ansa Biotechnologies located?

Ansa Biotechnologies is headquartered in Berkeley, United States. It is registered at Modesto, California.

How many employees does Ansa Biotechnologies have?

As of Mar 31, 2026, the latest employee count at Ansa Biotechnologies is 72.

Is Ansa Biotechnologies a funded company?

Ansa Biotechnologies is a funded company, having raised a total of $177M across 8 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 2018.

When was the latest funding round of Ansa Biotechnologies?

Ansa Biotechnologies' latest funding was a $***** Series B round on Oct 02, 2025, with participation from 6 investors.

Where does Ansa Biotechnologies rank among its competitors?

Ansa Biotechnologies ranks 2nd amongst 47 active competitors, of which 14 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Ansa Biotechnologies, which secured $54.4M in Oct, 2025.

Who are the top competitors of Ansa Biotechnologies?

Ansa Biotechnologies' top competitors include Twist Bioscience, Sensible Biotechnologies and Nutcracker Therapeutics. Among them, Ansa Biotechnologies secured the most recent funding round in October, 2025.

Ansa Biotechnologies - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of DNA synthesis technology using enzymes. The company offers a chemical method and Next-generation technology for synthesis. Their technology is based on polymerase-nucleotide conjugates that have the ability to extend a DNA molecule by one building block at a time.

Website: ansabio.com
Social
Email ID: *****@ansabio.com
Registered Address: Modesto, California

Key Metrics

Founded Year

2017

Location

Berkeley, United States

Stage

Series B

Total Funding

$177M in 8 rounds

Latest Funding Round

Series B, Oct 02, 2025, $*****

Investors

Horizons Ventures & 16 more

Ranked

2^nd among 47 active competitors

Employee Count

72 as on Mar 31, 2026

Similar Companies

Twist Bioscience & 55 more

View Ansa Biotechnologies' full profile

Ansa Biotechnologies is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ANSA BIOTECHNOLOGIES INC CIN: 830744780 , United States, Active	Dec 31, 1999	-	68 (As on Dec 31, 2024)	-
INDEPENDENT PHYSICIAN ASSOCIATES DBA ALL CARE CIN: 770243333 , Belgium, Active	Dec 26, 999	-	181 (As on Dec 31, 2022)	-

Ansa Biotechnologies has raised a total funding of $177M over 8 rounds. Its first funding round was on Dec 2018. Its latest funding round was a Series B round on Oct 02, 2025 for $*****. 6 investors participated in its latest round. Ansa Biotechnologies has 17 institutional investors.

Here is the list of recent funding rounds of Ansa Biotechnologies:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 02, 2025	6492716	Series B	2588493	5856640	7815797	6241449
Jun 28, 2024	7380565	Series A	1131503	4848145	1812569	3286061
Apr 13, 2022	2133610	Conventional Debt	2185869	6458945	5517393	9548202

Access funding benchmarks and valuations. Sign up today!

View details of Ansa Biotechnologies's funding rounds and investors

The founders of Ansa Biotechnologies are Daniel Lin-Arlow and Sebastian Palluk.

Here are the details of Ansa Biotechnologies' key team members:

Daniel Lin-Arlow: Co-Founder & CSO of Ansa Biotechnologies. They serve on the board of 1 company.
Sebastian Palluk: Co-Founder & CTO of Ansa Biotechnologies. They serve on the board of 1 company.
Contact Info: 1 email address

Ansa Biotechnologies' Board of Directors

Ansa Biotechnologies's board has 4 active members. Daniel Lin-Arlow, Sebastian Palluk, Lily Li and Daniel Hillel Lin-Arlow are independent board members.

Here is the list of Ansa Biotechnologies' board of directors:

Name	Type	Representing	Status	Duration
Daniel Lin-Arlow	Independent board member	-	Current	4y 5m
wobuqhc	Independent board member	-	Current	8y 4m
jlazoou	Independent board member	-	Current	3y 4m
sghhxyp	Independent board member	-	Current	9y 8m

View details of Ansa Biotechnologies's Founder profiles and Board Members

Ansa Biotechnologies' employee count trend

Ansa Biotechnologies has 72 employees as of Mar 26. Here is Ansa Biotechnologies's employee count trend over the years:

Employee count trend for Ansa Biotechnologies

Uncover Ansa Biotechnologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ansa Biotechnologies include Twist Bioscience, Sensible Biotechnologies and Nutcracker Therapeutics. Here is the list of Top 10 competitors of Ansa Biotechnologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Twist Bioscience 2013, San Francisco (United States), Public	Developer of a semiconductor-based DNA synthesis platform	$321M	Foresite Capital, Fidelity Investments & 39 others	70/100
2nd	Ansa Biotechnologies 2017, Berkeley (United States), Series B	Provider of DNA synthesis technology using enzymes	$177M	RA Capital Management, Mubadala & 15 others	64/100
3rd	Sensible Biotechnologies 2021, Wilmington (United States), Seed	Developer of mRNA technology for therapeutics and vaccines	$4.32M	BlueYard, Y Combinator & 6 others	58/100
4th	Nutcracker Therapeutics 2018, Emeryville (United States), Series C	Developer of mRNA therapeutics	$227M	Arch Venture Partners, ND Capital & 3 others	56/100
5th	OriCiro Genomics 2018, Tokyo (Japan), Acquired	Developer of technologies for DNA synthesis and amplification	$10.9M	UTEC, Asahi Kasei & 3 others	48/100
6th	Synbio Tech 2013, Suzhou (China), Seed	Synthetic biology techniques and bioinformatic tools for gene synthesis, cloning and antibody optimization	-	Alwin Capital, Co-win Ventures & 1 others	47/100
7th	DNA Script 2014, Paris (France), Series C	Developer of benchtop DNA printer for nucleic acid synthesis	$315M	Baillie Gifford, Coatue & 27 others	47/100
8th	Mesa Biotech 2009, San Diego (United States), Acqui-Hired	Provider of point-of-care molecular diagnostic kits	$26.8M	Public Health Emergency, VIDANT Capital & 3 others	45/100
9th	Cambrian Genomics 2011, San Francisco (United States), Series A	Genomics company focused on understanding, manipulating, and improving human health	$11.2M	Edelweiss, Felicis Ventures & 11 others	42/100
10th	Camena Bioscience 2016, Cambridge (United Kingdom), Series A	Developer of a nucleic acid synthesis technology platform	$10M	Mercia & 15 others	41/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Ansa Biotechnologies's competitors? Click here to see the top ones

Ansa Biotechnologies has made no investments or acquisitions yet.

Here is the latest report on Ansa Biotechnologies's sector:

Free

Internet of Things - Sector Report

Edition: January, 2026 (86 Pages)

View all reports related to Ansa Biotechnologies

Media has covered Ansa Biotechnologies for a total of 4 events in the last 1 year, 2 of them have been about people movement and 1 about partnerships.